Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - hydromorphone hydrochloride, quantity: 2 mg - injection, solution - excipient ingredients: citric acid; hydrochloric acid; sodium citrate dihydrate; sodium hydroxide; water for injections; sodium chloride - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - hydromorphone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; citric acid; sodium hydroxide; water for injections; sodium citrate dihydrate - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Israel - English - Ministry of Health

rafa laboratories ltd - hydromorphone hydrochloride - capsules slow release - hydromorphone hydrochloride 4 mg - hydromorphone - hydromorphone - for the relief of severe pain in cancer.

Israel - English - Ministry of Health

rafa laboratories ltd - hydromorphone hydrochloride - capsules slow release - hydromorphone hydrochloride 8 mg - hydromorphone - hydromorphone - for the relief of severe pain in cancer.

Israel - English - Ministry of Health

rafa laboratories ltd - hydromorphone hydrochloride - capsules slow release - hydromorphone hydrochloride 24 mg - hydromorphone - hydromorphone - for the relief of severe pain in cancer.

United States - English - NLM (National Library of Medicine)

ethex corporation - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - tablet - 2 mg - hydromorphone hydrochloride tablets are indicated for the management of pain in patients where an opioid analgesic is appropriate. hydromorphone hydrochloride tablets are contraindicated in patients with a known hypersensitivity to hydromorphone, patients with respiratory depression in the absence of resuscitative equipment, and in patients with status asthmaticus. hydromorphone hydrochloride tablets are also contraindicated for use in obstetrical analgesia. hydromorphone hydrochloride tablets contain hydromorphone, a schedule ii controlled opioid agonist. schedule ii opioid substances which include morphine, oxycodone, oxymorphone, fentanyl, and methadone have the highest potential for abuse and risk of fatal overdose. hydromorphone can be abused and is subject to criminal diversion. opioid analgesics may cause psychological and physical dependence. physical dependence results in withdrawal symptoms in patients who abruptly discontinue the drug. physical dependence usually does not occur to a clinically sign

United States - English - NLM (National Library of Medicine)

stat rx usa llc - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 2 mg - hydromorphone hydrochloride tablets usp are indicated for the management of pain in patients where an opioid analgesic is appropriate. hydromorphone hydrochloride tablets are contraindicated in: patients with known hypersensitivity to hydromorphone, patients with respiratory depression in the absence of resuscitative equipment, and in patients with status asthmaticus. hydromorphone hydrochloride tablets are also contraindicated for use in obstetrical analgesia. hydromorphone is an opioid agonist of the morphine-type. such drugs are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. hydromorphone hydrochloride tablets can be abused in a manner similar to other opioid agonists, legal or illicit. this should be considered when prescribing or dispensing hydromorphone hydrochloride tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. prescribers should monitor all patients receiving opioids for si

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2)] , reserve hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.7)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitati

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride extended-release tablets are indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. patients considered opioid tolerant are those who are receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations, [see warnings and precautions (5.1)], reserve hydromorphone hydrochloride extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immedia

United States - English - NLM (National Library of Medicine)

ascent pharmaceuticals, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride extended-release tablets are indicated for the management of pain in opioid-tolerant patients severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. patients considered opioid tolerant are those who are receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve hydromorphone hydrochloride extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or w